Hospital Universitario 12 de Octubre-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

2020

  1. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine

    Cancer Chemotherapy and Pharmacology, Vol. 86, Núm. 1, pp. 45-54

2019

  1. Comments on: “Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan”

    Pharmacological Research

2018

  1. Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan

    Pharmacological Research, Vol. 136, pp. 133-139

  2. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098

2017

  1. Identification of new SNPs associated with severe toxicity to capecitabine

    Pharmacological Research, Vol. 120, pp. 133-137

  2. Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity

    Pharmacogenomics, Vol. 18, Núm. 13, pp. 1215-1223

2015

  1. Variants in CDA and ABCB1 are predictors of capecitabinerelated adverse reactions in colorectal cancer

    Oncotarget, Vol. 6, Núm. 8, pp. 6422-6430